Stallergenes Greer and Anergis Report Successful Preclinical Study Results With COP-virosomes as Second-generation Allergen Immunotherapy
Stallergenes Greer, a worldwide leader in allergen immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development, today announced the results of a joint research study evaluating the effects of second-generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch pollen allergy, with the aim of shortening AIT administration schemes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005066/en/
COP-Virosomes, COP alone and virosomes alone were compared to a placebo group in an in-house therapeutic model of birch pollen allergy. Recombinant Bet v 1 alone (the major allergen of birch pollen) and natural birch pollen allergen extract were also used as controls in this setting.
COP-virosomes were the only synthetic therapy able to fully reverse asthma symptoms as well as lung inflammation (i.e. significant reduction in eosinophils in bronchial fluids). Pro-allergenic immune responses also decreased with COP-virosomes therapy with a significant decrease of the IL-4, a Th2 cytokine. The results of the study will soon be published.
“These new data confirm that COP-virosomes are likely to be more efficacious clinically than a recombinant allergen or than the first generation of COP allergy vaccines which did not include the Mymetics virosomes. COP-virosomes may thus represent a breakthrough AIT treatment of the future”, said Vincent Charlon, CEO of Anergis.
“The results of this new study demonstrate the potential of COP-virosomes in allergy immunotherapy treatments. During these unprecedented times, Stallergenes Greer remains committed to furthering research to provide patients with long-lasting relief from the burden of allergies and improving their quality of life,” concluded Amer Jaber, Executive VP Operations Europe and President of Stallergenes SAS.
About Allergen immunotherapy
Allergies are the most prevalent and fastest growing chronic diseases in the industrialised world, affecting over one billion people worldwide. Allergen immunotherapy uniquely alters the natural course of respiratory allergies. It is the only therapeutic class capable of modifying disease progression and potentially preventing the onset of the disease by inducing tolerance in the immune system.
About Stallergenes Greer
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Anergis SA is a Swiss biopharmaceutical company dedicated to the discovery and development of proprietary ultra-fast allergy immunotherapy products for the most prevalent allergies. Anergis was founded by Professor François Spertini, allergist at the University Hospital of Lausanne, Switzerland. Anergis raised over CHF 55 million from private and institutional investors, including BioMedInvest, Sunstone Capital, Renaissance PME and WJFS, Inc. Anergis SA is located in the Biopôle near Lausanne, Switzerland, a life sciences community bringing together industry and academia.
+33 (0)1 55 59 26 05
Vincent Charlon, CEO, firstname.lastname@example.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RELX Outlines at the GTNF Role of Technology in Advancing Vaping Industry’s Responsible Practices21.9.2020 14:29:00 CEST | Press release
The company’s Global External Affairs Lead provided concrete examples of how RELX has been harnessing the power of technology, innovation and research in its quest to forge ahead robust youth prevention mechanisms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005456/en/ Jonathan Ng speaking at the GTNF Innovations on the Horizon panel. (Photo: Business Wire) At the virtual Global Tobacco & Nicotine Forum (GTNF) event yesterday, RELX Technology’s Global Head of External Affairs Jonathan Ng spoke on a panel entitled “Innovations on the Horizon.” The panel explored several topics related to the growing international acceptance of e-cigarettes as better alternatives to cigarettes, innovations related to user experience and youth prevention, and illicit trade. GTNF is one of the leading tobacco and nicotine forums in the world; speakers and attendees include public health experts, government representatives, investors and
CHMP Grants Positive Opinion for Expanded Use of Otsuka’s Deltyba ® (delamanid) in Children and Adolescents Weighing at Least 30kg Treated for Pulmonary Multi-drug Resistant Tuberculosis21.9.2020 13:12:00 CEST | Press release
Otsuka Novel Products GmbH (ONPG), a subsidiary of Otsuka Pharmaceutical Co., Ltd., is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of extension of the indication for Deltyba® (delamanid) for children. This means Deltyba® (delamanid) is recommended by the CHMP for use as part of an appropriate combination regimen for pulmonary MDR-TB in adults, adolescents and children with a body weight of at least 30kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. According to the current World Health Organization Global TB Report, an estimated 1.1 million children (0-14 years of age) fell ill with TB in 2018.2 Each year, approximately 25,000-32,000 children fall ill with MDR-TB. Of these, only 3-4% are diagnosed and treated and consequently, approximately 21% of children with MDR-TB are likely to die.1 New global targets set at the UNs High Le
Visa Helps Prepare Small Businesses for the Holiday Buying Season as National Small Business Week Begins21.9.2020 13:00:00 CEST | Press release
As the Small Business Administration’s (SBA) National Small Business Week begins in the U.S. and businesses worldwide prepare for an unprecedented holiday season, Visa (NYSE: V) is introducing new programs and resources essential to small and micro business (SMB) recovery efforts. The Visa Back to Business Study, Holiday Edition, launched today, finds that consumers will carry their resolve for normalcy into the holiday shopping season, with 88% planning to buy and give gifts despite challenges the pandemic has created. To prepare for this unprecedented holiday season, SMBs should be looking for ways to offset the impact of COVID-19 during the holidays, with 60% already saying they are taking steps to prepare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005150/en/ Visa’s Back to Business kits include new “tap to pay preferred” point-of-sale materials, branding, educational resources and special offers. (Photo: Busin
"If Agroaceite Grows, Our Communities Grow, Too"21.9.2020 13:00:00 CEST | Press release
This is one of our principles at Agroaceite, as pointed out by José Javier Aguirre, Corporate Director of the tropical oil company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005269/en/ Agroaceite's Human Development Center facilities. "Some time ago I had the opportunity to visit Agroaceite ́s medical center, which is managed in collaboration with the University of Colorado. I was pleasantly impressed by the high quality service offered to the surrounding community. This is a good example of the kind of impact that RSPO certification aims to achieve: to improve people’s quality of life within the company ́s area of influence." FRANCISCO NARANJO, RSPO Representative for Latin America. (Photo: Business Wire) "Since Agroaceite was founded, the vision of social responsibility has been clear. Our main asset is our employees, and our best allies are the communities. As Agroaceite succeeds, communities must develop to th
Sagemcom AMI Solution, a Key Driver in the Swedish Energy Transition to a Sustainable Future21.9.2020 10:30:00 CEST | Press release
In September, ELLEVIO will continue to improve the Swedish electricity system by being one the first Nordic DSO to start its 2nd generation smart meters large scale rollout. This massive rollout is the result of joint achievements between ELLEVIO, Sagemcom and its local Partner, ONE Nordic. Since the award in March 2019, Sagemcom has developed and delivered a new generation of S211 single phase meters and T211 polyphase meters which allow ELLEVIO to take up the new energy landscape and customer care. The advanced deep indoor dual cellular technology LTE NB IoT + LTE Cat-M is used to secure the reliability of the solution. In less than 8 months and within a specific context, Sagemcom has developed and certified the new generation of smart meters which are installed in the field by ONE Nordic since June 2020 in Stockholm area. The new key features have already been deployed offering a combination of end-user experience - through a customer local interface (P1 Port) - and Low-Voltage netw
Market Failure? kENUP and YUVEDO High-Level Online Event Kick-starts Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases .21.9.2020 10:14:00 CEST | Press release
On Friday, 18 September 2020, YUVEDO Foundation and kENUP Foundation held a high-level online conference to kick-start an open public call for projects tackling the growing threat of Parkinson’s (PD) and other neurodegenerative diseases (NDD). Despite the predictable medical, social and economic challengesof NDDs, too little has happened in recent years to address the underlying causes of NDDs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005283/en/ Market and Regulatory Failure? High-Level Online Conference Kick-starts Open Public Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases (Photo: Business Wire) An expert report by Professor Maier-Rigaud of NERA Economic Consulting presented at the conference, showed that there are indications for market and regulatory failure around the development of interventions against PD and other NDDs: High risk in product development is
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom